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Background: Serum alkaline phosphatase (ALP) is a complex phenotype influenced by both genetic and
environmental factors. Recent Genome-Wide Association Studies (GWAS) have identified several loci affecting ALP
levels; however, such studies in Chinese populations are limited. We performed a GWAS analyzing the association
between 658,288 autosomal SNPs and serum ALP in 1,461 subjects, and replicated the top SNPs in an additional
8,830 healthy Chinese Han individuals. The interactions between significant locus and environmental factors on
serum ALP levels were further investigated.
Results: The association between ABO locus and serum ALP levels was replicated (P = 2.50 × 10-21, 1.12 × 10-56 and
2.82 × 10-27 for SNP rs8176720, rs651007 and rs7025162 on ABO locus, respectively). SNP rs651007 accounted for
2.15% of the total variance of serum ALP levels independently of the other 2 SNPs. When comparing our findings
with previously published studies, ethnic differences were observed across populations. A significant interaction
between ABO rs651007 and overweight and obesity was observed (FDR for interaction was 0.036); for individuals
with GG genotype, those with normal weight and those who were overweight or obese have similar serum ALP
concentrations; minor allele A of rs651007 remarkably reduced serum ALP levels, but this effect was attenuated in
overweight and obese individuals.
Conclusions: Our findings indicate that ABO locus is a major determinant for serum ALP levels in Chinese Han
population. Overweight and obesity modifies the effect of ABO locus on serum ALP concentrations.
Keywords: Genetic variations, Serum alkaline phosphatase, Heterogeneity, GWAS, Gene-environment interactionBackground
Alkaline phosphatases (ALP), which is essential in bone
mineralization and functions in vascular calcification [1], is
a group of hydrolytic isoenzymes with low substrate
specificity that catalyze the hydrolysis of organic phos-
phate esters at an alkaline environment [2]. Four genes
encode ALP, including tissue-nonspecific ALP gene located
on 1p36.12, which is expressed in various tissues such
as osteoblasts, hepatocytes, kidney and early placenta;* Correspondence: hemeian@hotmail.com
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reproduction in any medium, provided the orand three tissue-specific ALP genes located on 2q37,
which are expressed in placenta, germ cells, and intestine,
respectively [3]. In healthy individuals, serum ALP derives
mostly from liver/bone/kidney, partially from intestine
especially during postprandial time or in blood type O or
B secretors, and little is contributed from placenta in the
third trimester of pregnancy [4,5]. The concentration of
serum ALP is elevated in pathological conditions like
osteoblast activated bone disorders, bile-flow obstructions,
tumor metastases, liver diseases, leukemia, hyperthyroid-
ism, infections and obesity, while lower level occurs in
anemia and hypothyroidism [2,6]. Current evidence dem-
onstrated that elevated serum ALP levels were associated
with adverse outcomes of dialysis patients and increasedhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In particular, positive associations between ALP levels and
all-cause death rate together with cardiovascular mortality
were also observed in the general population [9]. Therefore,
investigating the underlying factors that influence serum
ALP levels are meaningful for both clinical medicine and
public health.
Serum ALP is a complex trait influenced by both
polygenic and environmental factors. It is reported that
age, gender, smoking, diet, body mass index (BMI), and
physical activities could affect serum ALP concentrations
[4,10-13]. The additive genetic heritability of serum ALP
in mice is approximately 56% [14]. Recent GWAS have
identified several loci, including NBPF3-ALPL, ABCB11,
GPLD1, PPP1R3B, TRIB1, ABO, JMJD1C, REEP3, FADS2,
PMFBP1, DLG4, FUT2 and ABHD12, associated with
serum ALP levels in European ancestry populations,
Asian-Indians and Japanese populations [15-17], however,
such researches in populations of Chinese origin are
limited, and no study investigated gene-environment
interactions on serum ALP levels. In the present study,
we performed a GWAS in 1,461 subjects and replicated
the top SNPs in additional 8,830 healthy Chinese Han
individuals. The purposes of the study were to (i) detect
genetic determinants for serum ALP in Chinese Han
population; (ii) compare the present results with published
findings to seek heterogeneity among Chinese and other
populations and (iii) investigate the gene-environment
interactions on serum ALP levels.
Results
Characteristics of the study population
A total of 1,452 subjects (21.8% female, 63.05 ± 8.14 years
old) were included in the discovery set with a mean (SD)
serum ALP concentration of 90.02 (26.51) U/L; validation
were conducted in 8,830 individuals (58.2% female,
61.95 ± 7.83 years old) whose mean (SD) serum ALP
concentration was 90.26 (35.41) U/L. The demographics
of the study population together with information on
potential influencing factors of serum ALP are summarized
in Additional file 1: Table S1.
Association with alkaline phosphatase level
In GWAS stage, a total of 906,703 SNPs were genotyped
among 1,461 subjects in which 38,446 SNPs not mapped
on autosomes were excluded. After QC filtering, SNPs
with minor allele frequency (MAF) < 0.01, Hardy-Weinberg
Equilibrium (HWE) < 0.0001, and SNPs call rate < 95% were
excluded. Individuals with a call rate < 95% were also ruled
out for further analysis. Finally, 1,452 subjects with 658,288
autosomal SNPs were retained for association analyses,
with an overall call rate of 99.68%. Quantile - Quantile plot
revealed a good match between the distributions of the
observed P values and those expected by chance, and agenomic inflation factor of 1.011 suggested that population
stratification effects were negligible in our study sam-
ples (Additional file 2: Figure S1). The Manhattan plot
showed that 2p11.2 (lead SNP rs7594727, P = 3.70 × 10-5),
2p23.1 (lead SNP rs1383023, P = 2.30 × 10-6), 9q34.2
(lead SNP rs651007, P = 1.93 × 10-21) and 17q21.32
(lead SNP rs7214920, P = 2.55 × 10-6) were associated with
serum ALP at 5.0 × 10-5 significance level (Figure 1, Table 1).
The regional association plot revealed the SNP-ALP associ-
ations and linkage disequilibrium (LD) relations on 9q34.2
(Figure 2). The present study has 91.3% power to detect
SNPs that account for 2% of the ALP variance at 5 × 10-5
significance level; however, it has only 48.6% power to
detect SNPs at 5 × 10-8 significance level, hence 5 × 10-5
was set to be the cutoff point in SNP selection. Seven
SNPs met the selection criteria (see Method). Among
them, rs657152 on 9q34.2, which has been reported to
be associated with ALP in European and Japanese popula-
tion [16,17], was replicated with a P value of 5.88 × 10-9 in
our GWAS set. Therefore, we did not validate this SNP
in the second stage. The other 6 SNPs were selected for
further validation.
Three SNPs located within or near the ABO locus showed
significant association with serum ALP in validation popula-
tion (P = 6.63 × 10-16, P = 7.54 × 10-44 and P = 1.10 × 10-20
for rs8176720, rs651007, and rs7025162, respectively)
(Table 1). Using each SNP as a covariate, we performed
conditional analysis on the remaining 2 SNPs for their asso-
ciation with serum ALP. The results revealed that rs651007
was associated with serum ALP levels (P = 1.84 × 10-23)
independently of the other two SNPs, and it accounted for
2.15% of the total variance of serum ALP (Additional file 3:
Table S2). A significant difference in ALP levels among
different genetic-inferred ABO blood groups was observed
in GWAS dataset (ALP = 79.00 U/L, 80.86 U/L, 91.16 U/L
and 92.82 U/L in individuals with blood group A, AB, B
and O, P = 1.57 × 10-18), similar to previous reports [18,19].
To further explore whether the effect of the lead SNP
rs651007 was driven by ABO blood group, we introduced
ABO blood group into the multivariable linear regression
model. As expected, the association between ALP levels
and rs651007 dramatically reduced after ABO blood group
adjustment. (β =− 0.036, P = 0.029, data not shown). Other
three loci that mapped on 2p23.1 (rs1383023, P = 0.905),
2p12.2 (rs7594727 in CNNM3, P = 0.501) and 17q21.32
(rs7214920 close to RPRML, P = 0.912) failed to be rep-
licated (Table 1). The unbalanced distribution of the
demographic characteristics in the discovery and replica-
tion samples in the present study might partly contribute
to the lack of replication.
Genetic heterogeneity on ALP levels among studies
GWAS results of the present study were compared with
previously published studies that conducted in populations
Figure 1 Manhattan plot of genome-wide association analyses for ALP. The horizontal axis shows the chromosomal positions while the
vertical axis shows -log10 P values from the test of association by linear regression analysis. The red horizontal line shows the P value of 5.0 × 10-8,
and the blue horizontal line corresponds to a P value of 1.0 × 10-5.
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though ABO locus found in other populations has been
replicated in the present study, other loci identified in
one or two earlier studies failed to be replicated. We
did not observe positive signals on ALPL or GPLD1, which
has been reported in European and Japanese studies
(for ALPL, P for lead SNP is 7.0 × 10-15, 5.08 × 10-13 and in
3.70 × 10-2 in European study, Japanese study and the
present study, respectively; for GPLD1, P for lead SNP
is 1.2 × 10-11, 2.13 × 10-11 and in 1.61 × 10-3 in European
study, Japanese study and the present study, respectively).
Many loci identified in populations of European origin,
e.g. ABCB11, PPP1R3B, C9orf125, REEP3, ST3GAL4 and
ABHD12, are neither significant in Japanese populations
nor in our population although some of them got com-
parable effect sizes across studies (e.g. for rs12355784
on JMJD1C, P = 5.0 × 10-10, 8.66 × 10-3 and 1.60 × 10-2,
and effect size = 0.025, 0.049 and 0.029 in European study,
Japanese study and the present study, respectively). Only
rs7173947, which mapped on an intergenic region on
chromosome 15, has been identified in Japanese population
with no significant signals around the locus being seen in
European or in the present study. The heterogeneity test
showed considerable heterogeneity across studies for some
SNPs (e.g. for rs2242420 on ALPL, P of Q = 2.61 × 10-6,
I2 = 0.955), which may attribute to ethnic heterogeneity
and differences in characteristics of samples and study
designs, etc. The small sample size also limited the power
of the present study to replicate SNPs with low MAF
and/or minor effects (for SNPs that explain 1.0% of the
ALP variance with MAF of 0.05, a sample size of 2,400
is needed to detect the association with 80% discovery
power at 5 × 10-5 significance level).Gene-environment interaction analysis
Multiple factors have been proved to influence serum ALP
levels, including age, gender, BMI, smoking, drinking and
physical activity [10-13,20]. Therefore, we tested whether
the independent SNP rs651007 interacted with age, gender,
BMI (normal/overweight or obese), smoking or drinking on
affecting ALP concentrations. As shown in Additional file 4:
Table S3, rs651007 had a significant interaction with over-
weight and obesity on serum ALP levels (FDR = 0.036). For
GG genotype carriers, the mean of serum ALP were simi-
lar between those with normal weight and those who were
overweight or obese (89.52 U/L in overweight and obese
subjects vs. 89.93 U/L in subjects with normal weight);
GA or AA genotype carriers have significantly decreased
serum ALP concentrations compared with GG genotype
carriers; however, this effect was attenuated in overweight
or obese individuals (β for rs651007 = −0.091 and −0.069
in subjects with normal weight and subjects who were
overweight or obese, respectively). Thus, among AA geno-
type carriers, overweight or obese individuals had higher
ALP levels than those with normal weight (81.24 U/L
in overweight and obese subjects vs. 77.93 U/L in normal
weight subjects) (Figure 3). The statistic power of inter-
action analysis in the present study is 71.1%. No significant
gene-environment interactions were observed between
rs651007 and other factors including age, gender, drinking,
and smoking (Additional file 4: Table S3).
Discussion
In the present two-stage GWAS, we confirmed that
previously identified locus ABO was associated with serum
ALP levels in a Chinese population. When comparing the
present study with previously published findings, ethnic
Table 1 SNPs associated with serum ALP levels
SNP Region Positiona Genes Locus Minor/major
allele
GWASb Validationb* Combinedb
MAF Effect size (s.e.m) P values MAF Effect size (s.e.m) P values MAF Effect size (s.e.m) P values
rs1383023 2p23.1 31872045 N/A - A/C 0.093 0.087 (0.018) 2.30 × 10-6 0.075 0.0016 (0.014) 9.05 × 10-1 0.080 −0.0009(0.005) 8.59 × 10-1
rs7594727 2p11.2 96853597 CNNM3 Intron A/C 0.107 −0.070 (0.017) 3.70 × 10-5 0.116 −0.008 (0.011) 5.01 × 10-1 0.113 −0.018(0.009) 4.39 × 10-2
rs8176720 9q34.2 135122694 ABO Exon C/T 0.444 0.055 (0.010) 8.19 × 10-8 0.454 0.038 (0.005) 6.63 × 10-16 0.452 0.041(0.004) 2.50 × 10-21
rs651007 9q34.2 135143696 SURF6-ABO Up- A/G 0.244 −0.114 (0.012) 1.93 × 10-21 0.222 −0.077 (0.005) 7.54 × 10-44 0.226 −0.079(0.005) 1.12 × 10-56
rs7025162 9q34.2 135156167 SURF6-ABO Up- A/G 0.390 −0.064 (0.011) 2.20 × 10-9 0.383 −0.044 (0.005) 1.10 × 10-20 0.384 −0.047(0.004) 2.82 × 10-27
rs7214920 17q21.32 42406128 RPRML Up- A/G 0.119 0.068 (0.016) 2.55 × 10-6 0.119 0.001 (0.011) 9.12 × 10-1 0.119 0.020(0.009) 2.99 × 10-2
aGenome position is based on NCBI build 36.3.
bThe P values in GWAS stage are based on linear regression analysis on the log-transformed ALP with adjustment for age, gender and the top two eigenvectors in PCA analysis assuming an additive model by PLINK.
The validation and combined P values are calculated by linear regression model on the log-transformed ALP and adjusted for age and gender.


















Figure 2 Regional association plot on 9q34 for SNP-ALP associations. The horizontal axis shows the chromosomal positions in the NCBI
build 36 genome sequences. In the upper part of the figure, the black dots represent P values of SNPs genotyped by Affymetrix SNP array. The
sky blue line shows the recombination rates given by the Hapmap release 22. The middle green arrows indicate the RefSeq genes. The lower
part of the figure shows a LD map of r2 values drawn by the Haploview software (http://www.broadinstitute.org/haploview/haploview) using
release 22 HapMap genotype data of the Chinese (CHB) and Japanese (JPT).
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significant interaction between overweight and obesity and
ABO rs651007 on serum ALP was found. The effects of
rs651007 on serum ALP levels were attenuated in over-
weight or obese individuals than in normal weight subjects.
The association between ABO locus and serum ALP has
been reported in other populations [15-17]. The present
study was consistent with previous findings that serum
ALP levels are much higher in individuals with blood type
B or O [18]; the lead SNP rs651007 on ABO locus, which is
in high LD with previously reported rs495828 (r2 = 0.916),
accounted for 2.15% of the total variance of serum ALP in
our population, similar with that reported in earlier studies
(2.0% for rs657152 in Europeans and 3.79% for rs495828 in
Japanese) [16,17]. The coding product of human ABO geneis a glycosyltransferase, of which catalytic activity could
facilitate the transfer of carbohytrates to H antigen to
form the antigenic structure of the ABO blood groups
[21]. Current evidence found that human ABO blood
groups or genetic variations on ABO gene were associated
with the risk of various diseases, such as pancreatic cancer,
gastric cancer, falciparum malaria, venous thromboembol-
ism, myocardial infarction and type 2 diabetes [22-28].
Genetic variations on ABO gene were also found to be
related with levels of serum E-selectin, sICAM, RBC, Hb,
vWF, and CEA [16,25,29]. In healthy fasted individuals,
approximately 90% of serum ALP originate from liver/
bone/kidney, nearly 10% from intestine and in some cases
1% from placenta [5]. Most of the intestinal ALP is attached
to ABO antigens on the surface of erythrocytes by a
Table 2 Ethnic differences in major genetic variants associated with serum ALP levels
SNP Gene Chr Effect
allele
Present study (Chinese)a Japaneseb CEUb P value
of Q
I2 No. of
studiesEAF Effect size P value EAF Effect size P value EAF Effect size P value
rs1780324 NBPF3-ALPL 1 T 0.29 0.020 9.56 × 10-2 0.28 0.075 7.14 × 10-5 0.44 0.031 7.0 × 10-15 0.051 0.664 3
rs2242420 ALPL 1 T 0.20 −0.032 3.70 × 10-2 0.18 0.163 5.08 × 10-13 0.14 - - 2.61 × 10-6 0.955 2
rs16856332 ABCB11 2 G 0.06 −0.026 0.270 0.07 - - 0.39 0.031 1.6 × 10-9 0.638 0.000 2
rs9467160 GPLD1 6 A 0.03 −0.032 0.369 0.003 −0.05 0.76 0.21 0.034 1.2 × 10-11 0.171 0.433 3
rs6911965 GPLD1 6 C 0.11 −0.056 1.61 × 10-3 0.66 −0.235 2.13 × 10-11 0.17 - - 5.35 × 10-6 0.952 2
rs6984305 PPP1R3B 8 A 0.01 0.010 0.863 0 - - 0.11 0.027 2.1 × 10-10 0.772 0.000 2
rs2954021 TRIB1 8 A 0.41 0.035 2.51 × 10-3 0.43 - - 0.50 0.014 2.3 × 10-13 0.095 0.641 2
rs10819937 C9orf125 9 C 0.36 0.020 0.114 0.32 - - 0.17 0.025 1.0 × 10-9 0.741 0.000 2
rs657152 ABO 9 T 0.46 −0.062 3.78 × 10-8 0.44 −0.223 1.35 × 10-38 0.38 −0.047 1.7 × 10-30 0 0.975 3
rs12355784 JMJD1C 10 C 0.33 0.029 1.60 × 10-2 0.50 0.046 8.66 × 10-3 0.49 0.025 5.0 × 10-10 0.558 0.000 3
rs10761779 REEP3 10 G 0.37 0.031 7.83 × 10-3 0.45 - - 0.49 0.025 6.9 × 10-10 0.634 0.000 2
rs174601 FADS2 11 A 0.41 0.007 0.563 0.38 - - 0.35 0.017 2.6 × 10-9 0.075 0.684 2
rs2236653 ST3GAL4 11 T 0.70 −0.024 4.40 × 10-2 0.60 - - 0.42 0.015 1.8 × 10-9 0.488 0.000 2
rs7173947 intergenic 15 C 0.33 −0.010 0.391 0.29 −0.105 3.23 × 10-8 0.41 - - 2.75 × 10-5 0.943 2
rs7186908 PMFBP1 16 C 0.22 −0.028 4.73 × 10-2 0.34 - - 0.24 0.02 4.8 × 10-9 1.35 × 10-3 0.903 2
rs314253 DLG4 17 G 0.51 0.005 0.658 0.52 - - 0.33 0.021 8.4 × 10-12 0.179 0.447 2
rs281377 FUT2 19 T 0.86 0.045 2.56 × 10-2 0.87 - - 0.43 0.018 1.1 × 10-15 2.42 × 10-3 0.891 2
rs7267979 ABHD12 20 G 0.07 −0.031 0.173 0.10 - - 0.57 0.015 7.4 × 10-10 0.484 0.000 2
aIn order to get genotypes of all reported SNPs, imputed genotype data were used in the presented ethnic comparison table. EAF is short for effect allele frequency.


















Figure 3 Box plot for interaction between rs651007 genotypes
and overweight and obesity. The vertical axis shows serum ALP
concentrations while the horizontal axis shows the BMI status
(normal weight/overweight and obese). Minor allele A diminished
serum ALP levels but this effect was attenuated in overweight or
obese individuals.
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blood type A bind to almost all intestinal ALP, while
erythrocytes of blood type B/O bind to a much lesser
degree, therefore results in a more prevalent presence
of intestinal ALP in serum in individuals with blood type
B/O [19,30]. In this sense, the differences in the binding
capacity between intestinal ALP and erythrocytes among
individuals with different blood groups might be a potential
mechanism underlying the association between ALP and
ABO locus identified in GWAS. The observation that asso-
ciation between rs651007 and serum ALP dramatically re-
duced after ABO blood group adjustment also lend support
to this deduction, indicating that ABO blood groups may
act as the driving force behind this association.
Differences were observed among studies when com-
paring our findings with previously published results
and parts of the reason might be due to the ethnic hetero-
geneity, such as varied effect allele frequencies and unique
LD structures. For example, the MAF of rs16856332 are
0.39, 0.06 and 0.07 in Europeans, Chinese and Japanese,
respectively; the MAF of rs9467160 on GPLD1 locus is
0.21 in European but is only 0.03 in Chinese Han, and
even lower, 0.003 in Japanese; the scenario is the same for
rs7267979 on ABHD12 that its effect allele frequency is
0.57 in European but is only 0.07 in Chinese. On the con-
trary, rs281377 has a MAF of 0.43 in European but the fre-
quency of this effective allele is 0.86 in Chinese. Meanwhile,not all ABO SNPs identified in Europeans are significant in
Chinese, which may partially due to the differences in
LD structure, e.g. the LD relation between rs8176720
and rs514708 on ABO gene is weak in Asian populations,
but get stronger in Europeans (r2 = 0.38, 0.36 and 0.67 in
the present, Japanese and European populations). Unique
population structures, including different modifier genes,
gene-gene or gene-environment interactions, different
lifestyles or environment exposures can also be explana-
tions for the heterogeneity across populations [31]. Notably,
although it showed no evidence for heterogeneity across
studies for SNPs on ABCB11, PPP1R3B, C9orf125, JMJD1C,
REEP3, ST3GAL4, and ABHD12, SNPs on ALPL, GPLD1,
PMFBP1 and FUT2 represented considerable heterogeneity
among studies. The lack of replication of many loci may
also due to different sample selection criteria, different
study designs and statistical analysis methods, as well as
the relatively small sample size of the GWAS stage of the
present study. Studies with larger sample size, different
ethnic sources and multi-center cooperations are needed
to explain the ethnic differences better.
Previous study found that serum ALP was higher in
obese patients [32]. The interaction between rs651007
and overweight and obesity on ALP levels found in the
present study may be one of the explanations. The effect
of rs651007 on serum ALP was attenuated in overweight
or obese individuals compared with normal weight subjects,
resulting in higher ALP levels in overweight or obese
individuals. eQTL analysis [33] showed that rs651007 could
trans-regulate the expression of TNFRSF1A (Effect = 0.403,
P = 1.30 × 10-5, LOD = 4.126); meanwhile, rs651007 was
observed associated to higher serum TNF-R2 levels in a
previous study [25], demonstrating that rs651007 may be
involved in the regulation of TNF receptors. In addition,
TNF signaling is believed playing an important role in obes-
ity since TNFα mRNA or protein was found overexpressed
in obese subjects in both experimental and epidemiological
studies. Researchers also found that TNF signaling plays
an important role in the insulin resistance of obesity
[34,35]. Moreover, TNF-α has been demostrated to posi-
tively regulate ALP levels in various types of cells [36-39].
Taken together, all evidence suggests that the interaction
between rs651007 and overweight and obesity on serum
ALP levels may act through the regulation of TNF system.
Further studies are needed to uncover the real mechanism
of the interaction.
Our study are not only consistent with findings of previ-
ous GWA studies [15-17], but also in line with early reports
that serum ALP levels varied in individuals with different
ABO blood types [2,4,18], However, it is undeniable that
the relatively small sample size of our GWAS stage limited
us to detect SNPs with minor effects and SNPs with low
MAF, which calls for further large sample size studies and
consortium cooperation.
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In summary, our study confirmed that ABO locus was a
major determinant for serum ALP levels in Chinese
Han population. When comparing the present study
with previously published findings, ethnic differences
were observed across populations. More importantly, we
found that overweight and obesity could modify the effects
of ABO rs651007 polymorphism on serum ALP levels.
Findings herein may furnish clinical application in progno-
sis control. Further studies are warranted to validate our
findings and explore the potential mechanisms.
Methods
Study subjects
We performed a two-stage GWAS for serum ALP
levels in individuals of Chinese Han origin, all of whom
were recruited from Dongfeng-Tongji cohort study
(DFTJ-cohort) in Hubei, China. DFTJ-cohort, which
includes 27,009 retired employees from a state-owned
automobile enterprise in China, was launched in 2008 and
will be followed up every 5 years. Detailed information
on demographics, lifestyle factors, baseline occupational
and environmental exposures has been collected and a
biospecimen bank (fasting blood serum, plasma, and DNA)
is available as well. The main goal of the study was to iden-
tify environmental and genetic risk factors for chronic dis-
eases, to investigate gene-environment interactions, and to
find novel biomarkers for chronic diseases prediction [40].
The discovery set (GWAS stage) included 1461 cohort
participants and the validation set (second stage) contained
another 8830 cohort subjects. Participants who were
deemed to be healthy in physical examinations were se-
lected, and those who have self-reported severe diseases,
such as stroke, coronary heart disease, cancers and dia-
betes mellitus, were excluded. The protocol was approved
by ethics committee in Tongji Medical College and all
subjects provided written informed consents.
Alkaline phosphatase measurement
Serum ALP levels were measured by ARCHITECT Ci8200
automatic analyzer (ABBOTT Laboratories. Abbott Park,
Illinois, U.S.A) using Abbott Diagnostics reagents following
standard experimental procedures from the manufacturer.
This measurement was accomplished by the Biochemical
Laboratory of Dongfeng Central Hospital, Shiyan, Hubei,
China together with the quantification of other biochemical
traits [40]. The intra-assay and inter-assay coefficients of
variation for ALP were 5.35% and 3.25%.
SNP genotyping and quality control
In discovery stage, a genome-wide genotyping scan in 1461
subjects was carried out using Affymetrix Genome-Wide
Human SNP Array 6.0 chips. High-quality genotyping
was performed by commercial company specialized inAffymetrix SNP array genotyping following standard
experimental procedures from the manufacturer. A total
of 906,703 SNPs were genotyped among 1,461 subjects in
which 38,446 SNPs not mapped on autosomes were
excluded. After QC filtering, SNPs with MAF < 0.01
(193,732 SNPs), HWE< 0.0001 (1,332 SNPs), and SNPs call
rate < 95% (17,764 SNPs) were excluded. Individuals with a
call rate < 95% were also ruled out for further analysis.
Finally, 1,452 subjects with 658,288 autosomal SNPs were
retained for statistical analyses, with an overall call rate of
99.68%. In validation stage, SNPs were genotyped using the
iPLEX system (Sequenom, Inc., San Diego, CA, USA), in
which all genotyping reactions were performed in 384-well
plates according to the manufacturer’s iPLEX Application
Guide (Sequenom, Inc.). Each plate included four randomly
selected duplicates, as well as six negative controls using
double distilled water. The average concordance rate for
genotyping in validation was 99.8%.
Statistical analysis
The population structure was evaluated by PCA using the
software package EIGENSTRAT 3.0 [41], and GWAS data
was analyzed utilizing PLINK 1.06 [42,43]. Quantile-quantile
plot was plotted by R 2.11.1 [44], Manhattan plot of -log10
P was generated with Haploview (v4.1) [45], and the regional
association plot was generated using SNAP [46]. To infer
ungenotyped SNPs [47], MACH 1.0 software [48] was ap-
plied to impute ungenotyped SNPs using LD information
from the HapMap phase II database (CHB + JPT as a
reference set (2007-08_rel22, released 2007-03-02)) [49].
Imputed SNPs with high genotype information content
(Rsq > 0.3) were kept for the further association analysis,
which was conducted using ProbABEL software [50,51]
Quanto 1.2.4 was used for power calculation [52]. BMI
was calculated as the individual’s body mass (kg) divided by
the square of his or her height (m2). Individuals whose BMI
was greater than or equal to 24 kg/m2 were defined as over-
weight and obese, otherwise were classed as normal weight
[53-55]. Individuals who had smoked at least one cigarette
per day for more than half a year no matter currently or
formerly were defined as smokers, otherwise were defined
as non-smokers. Those who had drunk at least once a
week for more than half a year no matter currently or
formerly were classed as drinkers, else were classed as
non-drinkers. Prior to analyses, serum ALP level was
nature log-transformed to normalize the distribution. For
GWA analysis, ALP-SNP associations were tested assuming
an additive genetic model using linear regression with age,
gender and the top two eigenvectors in PCA being included
as covariates. SNPs that met the following criteria were
selected for further validation: (1) SNPs with P ≤ 5.0 × 10-5
in GWAS stage; (2) when multiple SNPs showed strong LD
(r2 ≥ 0.8), SNP with the lowest P value was selected and (3)
MAF ≥ 0.05. In order to extract genotype information for
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http://www.biomedcentral.com/1471-2164/14/684all reported SNPs from the present study, imputed geno-
type data was used for ethnic comparisons. Loci that were
positive (P < 5.0 × 10-8 in GWAS stage) in either previously
published studies or the present study were gathered,
and representative SNPs on each locus were selected
and compared. GWAMA [56] was applied to calculate
heterogeneity among studies with the option of random
effect correction being abled.
SNP that showed a P < 0.05/6 in the validation dataset
or a P < 5 × 10-8 in the combined dataset is considered to
be statistically significant. For gene-environment interaction
analysis, we fitted linear regression models by adding
an interaction term of SNPs and environmental factors:
Y = α+ βs*SNP+ βse*SNP*environment + βe*environment +
βc*C; where SNP represented SNP to be tested (in the
present situation, rs651007); environmental factors in-
cluded age, gender, BMI (normal/overweight and obese),
smoking and drinking, which were introduced into the
model separately; and C represented covariates including
age and gender. We applied the false discovery rate
(FDR) approach [57] to control for multiple comparisons
(1 SNP × 5 environmental factors = 5 times) in the inter-
action analysis. Using each of the SNPs as a covariate, we
performed conditional analysis on the remaining 2 SNPs
on ABO gene for their association with ALP. The pro-
portion of the total serum ALP variation explained by
each SNP was measured by r2, which is the difference
of the model sum of squares between models with and
without the SNP of interest divided by the corrected
total sum of squares of the full model. Two tagging SNPs
(rs505922 and rs8176746) in ABO gene were used to infer
ABO blood group for each individual in GWAS dataset.
ABO blood group was set into a variable of integer
according to the reported binding capacity between ABO
antigen and ALP (A = 0, AB = 1, B = 2, O = 3) [19,30,58].
These analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC).
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